Related references
Note: Only part of the references are listed.Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Jedd D. Wolchok et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
Saskia J. A. M. Santegoets et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
CMV driven CD8+ T-cell activation is associated with acute rejection in lung transplantation
Antoine Roux et al.
CLINICAL IMMUNOLOGY (2013)
Immunosequencing: applications of immune repertoire deep sequencing
Harlan Robins
CURRENT OPINION IN IMMUNOLOGY (2013)
A Molecular Basis for the Control of Preimmune Escape Variants by HIV-Specific CD8+ T Cells
Kristin Ladell et al.
IMMUNITY (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Combining Next-Generation Sequencing and Immune Assays: A Novel Method for Identification of Antigen-Specific T Cells
Mark Klinger et al.
PLOS ONE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
Serena S. Kwek et al.
JOURNAL OF IMMUNOLOGY (2012)
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wenshi Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Unmasking the immune recognition of prostate cancer with CTLA4 blockade
Serena S. Kwek et al.
NATURE REVIEWS CANCER (2012)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
Begona Comin-Anduix et al.
PLOS ONE (2010)
Overlap and Effective Size of the Human CD8+ T Cell Receptor Repertoire
Harlan S. Robins et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Differential expression analysis for sequence count data
Simon Anders et al.
GENOME BIOLOGY (2010)
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong et al.
CANCER RESEARCH (2009)
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
Erika von Euw et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Brian Kavanagh et al.
BLOOD (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
Begona Comin-Anduix et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus:: Human Cytomegalovirus
Elizabeth K. Day et al.
JOURNAL OF IMMUNOLOGY (2007)
In vivo persistence of codominant human CD8+ T cell clonotypes is not limited by replicative senescence or functional alteration
Laurent Derre et al.
JOURNAL OF IMMUNOLOGY (2007)
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
Antoni Ribas et al.
ONCOLOGIST (2007)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses:: Spontaneous priming and efficient boosting by vaccination
Daniel E. Speiser et al.
JOURNAL OF IMMUNOLOGY (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor
BI Rini et al.
JOURNAL OF UROLOGY (2006)
T-cell grit:: large clonal expansions of virus-specific CD8+ T cells can dominate in the peripheral circulation for at least 18 years
JJ Miles et al.
BLOOD (2005)
Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses
L Trautmann et al.
JOURNAL OF IMMUNOLOGY (2005)
T cell receptor recognition motifs govern immune escape patterns in acute SIV infection
DA Price et al.
IMMUNITY (2004)
Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense
I Messaoudi et al.
SCIENCE (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
JG Egen et al.
IMMUNITY (2002)
Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6
F Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation
S Read et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
